碧海银沙1112015-04-11 12:21
Cellectis公司(ALCLS)(市场:ALCLS–纳斯达克全球市场:CLLS)一个开创性的基因排序公司在免疫肿瘤学领域采用专有技术开发最好的一流产品,今天宣布Cellectis公司将出席以下即将举行的会议:
波士顿癌症进展
日期:星期二,2015年4月14日时间:1:50 pm ET演示;
地点:约瑟夫-马丁会议...查看全文
琬麟2015-03-26 22:46
$CELLECTIS S.A.(CLLS)$ 跌破36那可就惨了,$ Juno Therapeutics (JUNO)$ $Bellicum Pharmaceuticals (BLCM)$ $SPARK THERAPEUTICS INC(ONCE)$ $Kite Pharma(KITE)$ 没有哪只股在开盘三日内跌成这样子的。查看全文
$Bellicum制药(BLCM)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-23-120984 Act: 34 Size: 219 KB 网页链接
$Bellicum制药(BLCM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-056578 Size: 22 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-23-039830 Act: 34 Size: 808 KB 网页链接
$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-038953 Act: 34 Size: 4 MB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001628280-23-033257 Act: 34 Size: 199 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 7.01 Accession Number: 0001628280-23-030016 Act: 34 Size: 186 KB 网页链接
$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-028893 Act: 34 Size: 4 MB 网页链接
$Bellicum制药(BLCM)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-23-000485 Act: 34 Size: 3 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 5.02 Accession Number: 0001628280-23-020619 Act: 34 Size: 197 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 3.01 Accession Number: 0001628280-23-020109 Act: 34 Size: 198 KB 网页链接